- NORTH AMERICA EDITIONAustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Scythian Biosciences Applies for Name and Ticker Symbol Change
Scythian Biosciences announced a name change for the company to Sol Global Investments Corp, the change will also apply to the company’s ticker symbol to “SOL.”
Scythian Biosciences (TSXV:SCYB) announced a name change for the company to Sol Global Investments Corp., the change will also apply to the company’s ticker symbol to “SOL.”
As quoted in the press release:
The Company will put the name change resolution before its shareholders at its next scheduled annual general meeting, which will be sometime in August 2018. The name change is also subject to approval by the TSX Venture Exchange (“TSXV”).
Rob Reid, CEO of Scythian, said that “SOL Global Investments better reflects our strategy of identifying and developing cultivation assets, nurturing branded products and opening up ancillary opportunities outside of Canada. SOL also embodies a balanced, positive and healthy way of life – something that’s increasingly important today. We look forward to this new chapter in our Company’s development.”
The Company also announces the grant of an aggregate of 480,000 options and 32,646 deferred share units (“DSUs”) to Rob Reid, CEO of the Company. The options were granted at an exercise price of $4.00per share and exercisable for a period of five years following the date of grant. 1/3 of the options vest as of the first anniversary following the grant date, 1/3 of the options vest as of the second anniversary following the grant date and the remaining 1/3 of the options vest as of the third anniversary following the grant date.
Click here to read the full press release.
Source: globenewswire.com
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.